Glenmark Pharmaceuticals (NSE:GLENMARK, BOM:532296) posted a consolidated profit attributable to owners of 3.01 billion Indian rupees in the fiscal fourth quarter, up from 46.5 million rupees a year earlier, according to a Friday filing by the pharmaceutical manufacturer.
Earnings per share for the quarter ended March 31 increased to 10.68 rupees from 0.16 rupees a year earlier.
Revenue from operations rose to 37.7 billion rupees from 32.6 billion rupees in the prior-year period.
Austco Healthcare (ASX:AHC) expects fiscal year 2026 revenue in the range of AU$90 million to AU$95 million, up 11% to 17% on fiscal year 2025 revenue of AU$81.4 million, according to a Monday Australian bourse filing.The company sees earnings before interest, taxes, depreciation, and amortization (EBITDA) in the range of AU$14 million to AU$14.6 million, up 7% to 12%, and EBITDA margin up almost 16%.The company said it has continued sales momentum across all regions, underpinned by new contract wins in New Zealand, Australia, Canada, and the US.The company's shares fell 18% in recent Monday trade, their lowest since late 2024.
Technology One (ASX:TNE) said Norges Bank raised its voting power in the firm to 6.1% from 5.05% on May 28, according to a Monday Australian bourse filing.The bank now holds nearly 20 million ordinary securities of the firm.Its shares rose 5% in recent trading on Monday.
ReadyTech (ASX:RDY) rejected the unsolicited, non-binding indicative proposal from Total Specific Solutions to acquire the company through a scheme of arrangement for a AU$2 per share cash consideration, according to a Monday filing with the Australian bourse.The proposal is parallel to an off-market bid with a 50.1% minimum acceptance condition as a cash consideration of $1.75 per share, the filing said.The proposal does not reflect the company's inherent value in a change of control context, and in any event would not be executable, per the filing.